Abstract
7220 Background: To observe the effects of concurrent radiotherapy combined with carboplatin and etoposide in limited stage small cell lung cancer. Methods: Ninty patients with limited stage small cell lung cancer were randomized into two groups, concurrent treatment group(group C) and alternating treatment group(group A). All patients in two groups received radiotherapy (60Gy in 30 fractions) and six courses of chemotherapy (carboplatin and etoposide). Radiotherapy was started in the first course of chemotherapy in group C. Patients of group A were treated by radiation between the fourth and the fifth course of chemotherapy. Results: The median survival time was 26 months in group C and 19 months in group A.The 5-year survival rate was 27% in group C and 16% in group A. The major toxic reactions were grade IIIĨV myelosuppression. The differences of two groups were significal(P<0.05). Conclusions: Concurrent radiotherapy combined with carboplatin and etoposide can significantly improve median survival time and 5-year survival rate of patients with limited stage small cell lung cancer. No significant financial relationships to disclose.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
